Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Boehringer Ingelheim

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Boehringer Ingelheim's 2013 sales performance.

Boehringer Ingelheim GmbH

Roche agrees $1.4bn takeover of fibrosis specialist Promedior

Roche agrees $1.4bn takeover of fibrosis specialist Promedior

At the moment, the only approved therapies for IPF are Roche/Shionogi’s Esbriet (pirfenidone) and Boehringer Ingelheim’s Ofev (nintedanib), which are both blockbuster drugs with sales in excess of

FDA advisors say no to empagliflozin in type 1 diabetes

FDA advisors say no to empagliflozin in type 1 diabetes Approval of Boehringer, Lilly-partnered drug expansion looks unlikely. Boehringer Ingelheim and Eli Lilly’s hopes of expanding the use of their empagliflozin drug into type 1 diabetes look out of ... That means Boehringer and Lilly now have to decide

AZ’s Farxiga gets heart failure prevention okay from FDA

AZ’s Farxiga gets heart failure prevention okay from FDA It’s also an important win for AZ as it tries to chase down SGLT2 inhibitor market leader Jardiance (empagliflozin) from Eli Lilly and Boehringer Ingelheim. ... Boehringer and Lilly are testing Jardiance in both HFrEF and HFpEF with two trials –

Novartis grows in Q3 thanks to stellar performance of key drugs

Novartis grows in Q3 thanks to stellar performance of key drugs Novartis has also been facing increasing competition in this therapy area, from the likes of Eli Lilly/Boehringer Ingelheim’s Jardiance and AstraZeneca’s Farxiga.

Finalists

Palmoplantar pustulosis augmented reality tool. by Boehringer Ingelheim. with support from OPEN Health. ... Excellence in Pharma Brand Management. The SPIRIVA RESPIMAT Success Story. by Boehringer Ingelheim.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...
What do Healthcare Professionals think about the inclusion of remote selling techniques?
Evolving to a digitally focused pharma / healthcare company - an organisational roadmap...
Drug pricing and competition
Strengthening business competition and reducing anti-competitive practices
How the CMA is tackling high prices for essential drugs...

Infographics